Abstract
About 10-15% of patients with multiple myeloma develop light chain (AL) amyloidosis. AL amyloidosis is a systemic disease that may involve multiple organs, often including the heart. It may present clinically with bradyarrhythmia and syncope. The proteasome inhibitor bortezomib has been used with clinical efficacy in treating patients with AL amyloidosis but also implicated as a possible cause of cardiomyocyte injury. We report a case of a 48- year-old man with AL amyloidosis and increased frequency of syncope and cardiac arrest after starting bortezomib. The biologic and clinical plausibility of a heightened risk for cardiac arrest in patients with cardiac AL amyloidosis and history of syncope being treated with bortezomib is a possibility that is not well documented in the medical literature and warrants further investigation.
| Original language | English |
|---|---|
| Article number | 6417 |
| Pages (from-to) | 27-28 |
| Number of pages | 2 |
| Journal | Hematology Reports |
| Volume | 8 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 10 2016 |
ASJC Scopus Subject Areas
- Hematology
Keywords
- Bortezomib
- Cardiac arrest
- Light chain amyloidosis
- Syncope